Loading clinical trials...

COMPLETEDPHASE2

MK3207 for Treatment of Acute Migraines (3207-005)

A Phase IIb, Multicenter, Randomized, Double-blind, Placebo-Controlled Dose-finding Study of MK3207 in the Treatment of Acute Migraine

NCT00712725•Merck Sharp & Dohme LLC

View on ClinicalTrials.gov

Summary

The purpose of the study is to demonstrate the effectiveness and appropriate dosage level of MK3207 in the treatment of acute migraine.

Eligibility

Age

18 - 65 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Men and Women from 18 to 65 years of age
•1+ year history of migraine that typically last from 4 to 72 hours if untreated
•Had from 2 to 8 moderate or severe migraine attacks per month in the last 2 months
•Not pregnant or planning to become pregnant in next 6 months

Exclusion Criteria

•Pregnant or breast-feeding, or planning to become pregnant in next 6 months
•Cannot distinguish migraine attacks from tension type headaches
•Migraines are mild or resolve without medication in less than 2 hours
•More than 15 headache-days per month or have taken medication on more than 10 days per month in the last 3 months
•Basilar type or hemiplegic migraine headaches
•More than 50 years old when migraines began
•History of cardiovascular disorder within last 6 months

Key Dates

Start Date

July 1, 2008

Primary Completion Date

January 1, 2009

Completion Date

January 1, 2009

Last Updated

February 2, 2015

Enrollment

676

ACTUAL participants

Conditions

Migraine

Interventions

MK3207- 2.5 mg

DRUG

MK3207- 5 mg

DRUG

MK3207- 10 mg

DRUG

MK3207- 20 mg

DRUG

MK3207- 50 mg

DRUG

MK3207- 100 mg

DRUG

Comparator: placebo (unspecified)

DRUG

A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine

NCT07018713

Chronic Migraine

View study

RECRUITINGPHASE3

A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine

NCT06641466

Menstrual Migraine

View study

RECRUITINGNA

Mind Body Balance for Pediatric Migraine

NCT04715685

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 2, 2015Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

MK3207 for Treatment of Acute Migraines (3207-005)

Inclusion Criteria

Exclusion Criteria

A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine

A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine

Mind Body Balance for Pediatric Migraine

Light Exposure, Migraine Outcomes, and Sleep Quality

A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine

Prophylactic Treatment With Atorvastatin for Episodic Migraine.